Drug Profile
Mesdopetam - Integrative Research Laboratories
Alternative Names: IRL-790Latest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Integrative Research Laboratories
- Developer Integrative Research Laboratories; Ipsen
- Class Amines; Antiparkinsonians; Antipsychotics; Fluorobenzenes; Phenyl ethers; Small molecules; Sulfones
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Parkinson's disease
- Phase I Drug-induced dyskinesia
- Preclinical Psychotic disorders
Most Recent Events
- 22 Mar 2024 IRLAB Therapeutics receives written minutes from a recent end-of-phase II meeting for mesdopetam with the US FDA
- 22 Feb 2024 Integrative Research Laboratories completes end of the phase II meeting with the FDA for mesdopetam
- 04 Jan 2024 Integrative Research Laboratories receives end-of-phase II meeting approval from the US FDA for Parkinson's disease